John Lahart (Dublin South West, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

1997.To ask the Minister for Health if a plan is in place to ensure the HSE is equipped to administer radioligand therapy treatments for cancer by investing in the infrastructure, the highly trained personnel and models of care that are required. [31011/24]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

Radioligand therapy is a type of nuclear medicine that works by delivering targeted doses of radiation to cancer cells. One form of radioligand therapy licensed by the European Medicines Agency and approved for reimbursement by the HSE in the treatment of specific neuroendocrine tumours is called Peptide Receptor Radionuclide Therapy (PRRT). PRRT was made available in Ireland to patients with neuroendocrine tumours for the first time in 2023.

St. Vincent's University Hospital, Dublin, which is the national centre for neuroendocrine tumours, has been designated as the initial site for PRRT in Ireland and has been provided support for the development of the required infrastructure and training of staff for the provision of PRRT. This service was officially opened in March 2024. The HSE has approved the reimbursement of PRRT through the standard reimbursement assessment process.